Cancer Control,
Journal Year:
2024,
Volume and Issue:
31
Published: Jan. 1, 2024
Liver
cancer
(LivCa)
is
a
growing
concern
in
the
MENA
region,
driven
by
diverse
factors,
including
viral
hepatitis,
lifestyle-related
risks,
and
other
causes.
Clinical and Molecular Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 26, 2024
Hepatocellular
carcinoma
(HCC)
is
a
major
global
burden,
ranking
as
the
third
leading
cause
of
cancer-related
mortality.HCC
due
to
chronic
hepatitis
B
virus
(HBV)
or
C
(HCV)
infection
has
decreased
universal
vaccination
for
HBV
and
effective
antiviral
therapy
both
HCV,
but
HCC
related
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD)
alcohol-associated
(ALD)
increasing.Biannual
ultrasonography
serum
α-fetoprotein
are
primary
surveillance
tools
early
detection
among
high-risk
patients
(e.g.,
cirrhosis,
HBV).Alternative
such
blood-based
biomarker
panels
abbreviated
MRIs
being
investigated.Multiphasic
CT
MRI
standard
diagnosis,
histological
confirmation
should
be
considered,
especially
when
inconclusive
findings
seen
on
cross-sectional
imaging.Staging
treatment
decisions
complex
made
in
multidisciplinary
settings,
incorporating
multiple
factors
including
tumor
degree
dysfunction,
patient
performance
status,
available
expertise,
preferences.Early-stage
best
treated
with
curative
options
resection,
ablation,
transplantation.For
intermediatestage
disease,
locoregional
therapies
primarily
recommended
although
systemic
may
preferred
large
intrahepatic
burden.In
advanced-stage
immune
checkpoint
inhibitor
(ICI)-based
regimen.In
this
review
article,
we
discuss
recent
epidemiology,
risk
factors,
care
continuum
encompassing
surveillance,
staging,
treatments.
Hepatology International,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 11, 2025
Liver
cancer
(LC)
is
a
major
concern
in
the
Asia-Pacific
region,
particularly
China,
Korea,
and
Japan.
In
this
study,
we
aimed
to
investigate
burden,
trends,
predictions
related
LC
these
countries.
Using
data
from
Global
Burden
of
Disease
Study
2021,
epidemiological
characteristics
[incidence,
deaths,
disability-adjusted
life-years
(DALYs)]
for
were
analysed
stratified
by
specific
etiologies
Japan,
South
Korea.
We
examined
temporal
trends
burden
over
last
32
years
projected
changes
following
25
years.
The
risk
factors
associated
with
deaths
DALYs
also
investigated.
highest
LC-related
incidence,
mortality,
recorded
China
(196,637
incidents,
172,068
mortalities,
4,890,023
DALYs),
lowest
Korea
(18,642
13,674
326,336
DALYs).
age-standardized
rates
(ASRs)
(19.94
per
100,000,
14.53
354.57
100,000),
Japan
(9.89,
7.29,
145.74,
respectively).
From
1990
incidents
three
countries
increased,
ASRs
decreased.
caused
five
increased
past
years,
non-alcoholic
steatohepatitis
(NASH)
was
largest
increasing
China.
Infections
hepatitis
B
virus
remained
leading
cause
while
C
prevailing
High
body
mass
index
(BMI)
most
sharply
factor
Alcohol
drug
use
main
respectively.
rise
steadily
between
2022
2046.
remains
significant
disease
now
next
Regarding
factors,
NASH
high
BMI
alcohol
should
receive
attention.
BMC Public Health,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: Jan. 6, 2025
Gastrointestinal
(GI)
cancers
account
for
over
a
quarter
of
all
cancer-related
deaths
in
the
United
States;
however,
latest
trends
their
prevalence
remain
unclear.
Data
on
GI
were
obtained
from
Global
Burden
Disease
Study
2021.
Age-standardized
incidence
rates
(ASIR)
and
age-standardized
mortality
(ASMR)
estimated
across
various
states,
sexes,
ages,
risk
factors,
annual
percentage
changes
calculated.
From
2000
to
2021,
liver
cancer
exhibited
greatest
increase
both
ASIR
ASMR,
followed
by
pancreatic
cancer.
In
contrast,
stomach
showed
decline,
colorectal
cancer,
esophageal
biliary
tract
Most
predominantly
affect
men
tend
toward
younger
age
onset.
Geographic
disparities
exist
burden
factors.
For
esophageal,
stomach,
cancers,
linked
diet
smoking
decreased,
whereas
alcohol-related
increased
several
especially
West
Virginia.
Hepatitis
C
remains
leading
cause
with
intravenous
drug
use
as
primary
factor.
Non-alcoholic
steatohepatitis
(NASH)
is
fastest-growing
excessive
alcohol
use.
Mortality
due
high
body-mass
index
fasting
plasma
glucose
have
states
groups.
The
epidemiological
U.S.
shifted
substantially.
States
need
implement
targeted
policies
that
address
specific
populations
factors
each
type.
Drug Metabolism and Personalized Therapy,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 22, 2025
Abstract
Objectives
Hepatocellular
carcinoma
(HCC)
is
a
common
type
of
liver
cancer
that
progresses
quickly
and
has
limited
treatment
options.
Nutraceutical
anacardic
acid
(AA),
bioactive
compound
derived
from
cashew
nut
shell,
emerged
as
potential
candidate
for
HCC
owing
to
its
reported
anti-inflammatory,
anticancer
diverse
pharmacological
properties.
In
the
present
study,
we
investigate
AA
an
inhibitor
using
molecular
docking,
gene
ontology,
network
pharmacology.
Methods
The
pharmacokinetic
physicochemical
properties
were
assessed
Swiss
ADME.
SuperPred,
Similarity
Ensemble
Approach,
ChEMBL
Target
Prediction
online
tools
used
determining
targets
AA.
addition,
GeneCards,
NCBI,
DisGeNET
UniProt
ID
search
top
25
hub
genes
determined
Cytohubba
plugin.
A
protein
interaction
(PPI)
was
constructed
through
STRING
database.
Gene
Ontology
(GO)
biological
process
Kyoto
Encyclopaedia
Genes
(KEGG)
pathway
enrichment
analysis
performed
FunRich
ShinyGO
0.77.
Moreover,
docking
studies
on
NF-κB
GSK-3β.
expression
levels
also
validated
by
western
blotting.
Results
Comprehensive
data
identified
375
11,333
HCC,
with
264
in
common.
Network
key
targets,
including
caspase-3,
NF-κB.
ontology
topology
highlighted
essential
pathways
implicated
progression
such
renin-angiotensin
system,
VEGF
signalling,
apoptosis.
Molecular
revealed
strong
binding
affinity
proteins
Upregulation
p-NRF2
p-GSK-3β,
downregulation
p-NF-κB
caspase-1
Conclusions
Taken
together,
our
study
highlights
promising
chemopreventive
agent
because
significant
modulatory
effects
important
regulatory
linked
cell
division,
inflammation,
apoptosis,
antioxidant
response.
Chinese Medical Journal,
Journal Year:
2024,
Volume and Issue:
137(19), P. 2334 - 2342
Published: Sept. 3, 2024
Abstract
Background:
Liver
cancer
remains
the
sixth
most
commonly
diagnosed
and
third
leading
cause
of
cancer-related
deaths
worldwide,
causing
a
heavy
burden
globally.
An
updated
assessment
global
epidemiology
liver
that
addresses
geographical
disparities
is
necessary
to
better
understand
promote
healthcare
delivery.
Methods:
Data
were
extracted
from
GLOBOCAN
2022
database,
including
number,
crude,
age-standardized
rates
incidence
mortality
at
global,
country,
continent,
human
development
index
(HDI)
regional
levels.
Age-standardized
(incidence
mortality)
per
100,000
person-years
adjusted
based
on
Segi-Doll
World
standard
population.
The
mortality-to-incidence
ratios
(MIR)
for
each
region
country
calculated.
HDI
gross
national
income
(GNI)
obtained,
Pearson
correlation
analysis
was
conducted
with
incidence,
mortality,
MIR.
Results:
In
2022,
approximately
866,136
new
cases
758,725
related
recorded
MIR
0.86.
Males
had
disproportionately
higher
than
females
across
all
levels,
highest
observed
in
elderly
Geographically,
regions
included
Micronesia,
Eastern
Asia,
Northern
Africa,
Southeastern
Micronesia.
Notably,
Mongolia
strikingly
high
compared
other
countries.
North
America
lowest
Africa.
Negative
associations
GNI
identified,
irrespective
sex.
Conclusions:
current
underscores
presence
remarkable
geographic
heterogeneity,
which
particularly
evident
countries
varying
highlighting
urgent
need
prioritize
health
accessibility
availability
achieve
inequities.
Gastroenterology report,
Journal Year:
2023,
Volume and Issue:
12
Published: Dec. 22, 2023
Abstract
Chronic
liver
disease
presents
a
significant
global
health
burden,
characterized
by
several
etiologies,
including
metabolic
dysfunction-associated
steatotic
(MASLD),
alcohol-related
(ALD),
chronic
hepatitis
B
virus
infection,
and
C
infection.
This
review
explored
current
epidemiological
trends
projections
for
each
etiology,
looking
into
their
respective
burdens
challenges.
MASLD,
formerly
known
as
nonalcoholic
fatty
disease,
is
the
most
prevalent
cause
of
its
incidence
prevalence
are
steadily
rising.
ALD,
fueled
increased
alcohol
consumption,
also
on
rise,
with
concerning
implications
future
mortality
rates.
infections
remain
major
public
concerns,
particularly
in
specific
regions
world,
necessitating
concerted
efforts
screening
treatment.
The
coronavirus
2019
(COVID-19)
pandemic
has
impacted
epidemiology
exacerbating
rates
disrupting
healthcare
services.
Mental
issues
arising
from
further
complicate
treatment
making
comprehensive
strategies
essential.
Despite
advancements
treatment,
continues
to
impose
substantial
economic
emphasizing
importance
preventive
measures
early
intervention.
In
conclusion,
ongoing
surveillance
research
crucial
understanding
addressing
evolving
landscape
disease.
Comprehensive
that
encompass
prevention,
screening,
different
etiologies
essential
mitigating
impact
improving
patient
outcomes.